Sonntag, Juli 31, 2022
StartBiotechnologyAtreca to Current at Upcoming Investor Conferences – Bio Tech Winners

Atreca to Current at Upcoming Investor Conferences – Bio Tech Winners


Final Up to date on Might 19, 2022 by GlobeNewsWire

SAN CARLOS, Calif., Might 19, 2022 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology firm centered on creating novel therapeutics generated by means of a singular discovery platform based mostly on interrogation of the energetic human immune response, at this time introduced that it’ll current on the following upcoming investor conferences:

H.C. Wainwright World Funding Convention
Might 23-26, 2022
Presentation: 8:30 am EDT, Might 25, 2022

Cowen’s third Annual Oncology IO Subsequent Summit
June 2, 2022
Presentation: 2:00 pm EDT, June 2, 2022

Jefferies Healthcare Convention
June 8-10, 2022
Hearth Chat: 9:00 am EDT, June 9, 2022

A stay audio webcast of every presentation may be accessed by means of the Occasions & Displays part of the Firm’s web site at http://ir.atreca.com. An archived replay can be obtainable on the Firm’s web site for 30 days following every occasion.

About Atreca, Inc.
Atreca is a biopharmaceutical firm creating novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca’s platform permits entry to an unexplored panorama in oncology by means of the identification of distinctive antibody-target pairs generated by the human immune system throughout an energetic immune response towards tumors. These antibodies present the idea for first-in-class therapeutic candidates, corresponding to our lead product candidate ATRC-101, a monoclonal antibody focusing on a novel RNP advanced, and ATRC-301, an ADC focusing on a novel epitope on EphA2. A Section 1b examine evaluating ATRC-101 in a number of strong tumor cancers is presently enrolling sufferers, and ATRC-301 is in IND-enabling research. For extra data on Atreca, please go to http://www.atreca.com.

Ahead-Wanting Statements
Statements contained on this press launch relating to issues that aren’t historic information are “forward-looking statements” throughout the that means of the Non-public Securities Litigation Reform Act of 1995. These forward-looking statements embrace, however usually are not restricted to, statements relating to our technique and future plans, together with statements relating to the event of ATRC-101, ATRC-301, and our preclinical and scientific plans and the timing thereof. Our precise outcomes could differ materially from these indicated in these forward-looking statements resulting from dangers and uncertainties associated to the initiation, timing, progress and outcomes of our analysis and growth packages, preclinical research, scientific trials, regulatory submissions, and different issues which might be described in our most up-to-date Annual Report on Type 10-Ok and Quarterly Report on Type 10-Q filed with the Securities and Trade Fee (SEC) and obtainable on the SEC’s web site at http://www.sec.gov, together with the danger components set forth therein. Traders are cautioned to not place undue reliance on these forward-looking statements, which communicate solely as of the date of this launch, and we undertake no obligation to replace any forward-looking assertion on this press launch, besides as required by regulation.

Contacts

Atreca, Inc.
Herb Cross
Chief Monetary Officer
data@atreca.com

Traders:
Alex Grey, 650-779-9251
agray@atreca.com

Media:
Julia Fuller, 858-692-2001
julia@fordhutmanmedia.com

Supply: Atreca, Inc.

RELATED ARTICLES

Most Popular

Recent Comments